, Volume 32, Issue 11, pp 1673-1675
Date: 05 Jul 2013

Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Introduction

Chronic anterior uveitis (CAU) is an important extra-articular manifestation of juvenile idiopathic arthritis (JIA).

Although the incidence of serious sight loss varies between series (6–25 %), CAU related to JIA (CAUJIA) is an important cause of blindness in children from developed countries [1, 2]. The severity of the complications obliges the use of prompt, aggressive treatment to prevent sequelae. In an attempt to spare glucocorticoids and avoid side effects, various immunosuppressive drugs have been used. Leflunomide (LFN) has proven to be safe and effective long-term therapy for the articular component of JIA [3]. To our knowledge, there is no available information about the efficacy of LFN in CAUJIA.

Materials and methods

A retrospective, observational study was performed to evaluate the efficacy and safety of LFN in the treatment of CAUJIA. Thirteen patients with CAU from our cohort of 417 children with JIA, all of whom had received LFN for at least 7 months to treat t ...